1. 1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. 2. Kim YS, Lim HK, Rhim H, Lee MW, Choi D, Lee WJ, Paik SW, Koh KC, Lee JH, Choi MS, Gwak GY, Yoo BC. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. J Hepatol 58: 89-97, 2013.
3. 3. Afdhal N, McHutchinson J, Brown R, et al. Thrombocytopenia associated with chronic liver disease. J Hepatol 48: 1000-1007, 2008.
4. 4. Maan R, de Knegt RJ, Veldt BJ. Management of thrombocytopenia in chronic liver disease: focus on pharmacotherapeutic strategies. Drugs 75: 1981-1992, 2015.
5. 5. Qamar AA, Grace ND, Groszmann RJ, et al; Portal Hypertension Collaborative Group. Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis. Clin Gastroenterol Hepatol 7: 689-695, 2009.